Liam Widjaja
6PUBLICATIONS
2CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Mar 01, 2026
[177Lu]Lu-PSMA radioligand therapy in younger prostate cancer patients: A matched-pair analysis between patients ≤ 65 and ≥ 70 years old.Johannes Hornfeck, Paul J Dahlmann, Sophie C Siegmund
|Feb 08, 2026
PET-based risk stratification for adverse events under [225Ac]Ac-PSMA radioligand therapy.Liam Widjaja, Sophie C Siegmund, Franz J Gildehaus
|Nov 01, 2025
Refining the clinical utility of [177Lu]Lu/[225Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer.Liam Widjaja, Johannes Hornfeck, Sophie C Siegmund
|Sep 22, 2022
Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy.Liam Widjaja, Rudolf A Werner, Elke Krischke
|Oct 11, 2021
Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.Liam Widjaja, Thorsten Derlin, Tobias L Ross
|Jul 02, 2021
PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy.Liam Widjaja, Rudolf A Werner, Tobias L Ross
Pageof 1
